Medicine
Advair HFA 230 mcg/21 mcg inhaler
Advair HFA 230 mcg/21 mcg inhaler is a prescription medicine containing Fluticasone propionate and Salmeterol for inhalation use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature between 68°F and 77°F (20°C and 25°C), excursions…
Key facts
- Active ingredient (INN)
- Fluticasone propionate and Salmeterol
- Brand
- Advair HFA
- Strength
- 230 mcg/21 mcg
- Dosage form
- Inhaler
- Route
- Inhalation
- Packs
- 1 inhaler
- Marketing authorisation holder
- GlaxoSmithKline
- Manufacturer
- GlaxoSmithKline
- Origin register
- US FDA, United States
- Storage
- Store at room temperature between 68°F and 77°F (20°C and 25°C), excursions permitted from 59°F to 86°F (15°C to 30°C). For best results, the inhaler should be at room temperature before use. Store the inhaler with the mouthpiece down.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R03AK06 Fluticasone propionate and Salmeterol
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 March 2009
- Identifiers
- RxCUI 896231, 896235, 896236 +7DailyMed set ID dfaca6f9-3277-47b2-319d-1377917cb54cNDC 0173-0717Application NDA021254
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 inhaler in 1 carton / 120 aerosol, metered in 1 inhaler | 0173-0717-20 | GlaxoSmithKline | 6 March 2009 |
| 1 inhaler in 1 carton / 60 aerosol, metered in 1 inhaler | 0173-0717-22 | GlaxoSmithKline | 6 March 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Fluticasone propionate and Salmeterol 230 mcg/21 mcg inhaler.
Other strengths and forms of Fluticasone propionate and Salmeterol
Clinical summary
Fluticasone propionate and Salmeterol is a fixed-dose combination of a corticosteroid and a beta2-adrenergic agonist indicated for twice-daily treatment of asthma in patients aged 4 years and older, among other approved uses. MedsAcross supplies Fluticasone propionate and Salmeterol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Fluticasone propionate and SalmeterolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ADVAIR DISKUS prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
- Seffalair Spiromax: European public assessment report (EPAR) · European Medicines Agency
Need Advair HFA 230 mcg/21 mcg inhaler for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.